Skip to content

Author

Yan Yu

We have 6 of 80 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC.

BACKGROUND Pembrolizumab plus chemotherapy with a platinum-based agent and pemetrexed is a widely used standard first-line treatment option for patients with programmed death ligand 1 (PD-L1)-negative advanced nonsquamous non-small-cell lung cancer (NSCLC) without targetable genomic alterations, but outcomes remain sub...

Fei Zhou, Xiang-Jiao Meng, Qing-Qing Ding et al. · 0 citations
Open access Nov 2026

TAVO412, an Anti-EGFR, cMET and VEGF Trispecific Antibody: Initial Results from a Phase I Dose Escalation Study in Patients with Advanced Solid Tumors.

PURPOSE We report the results of a Phase 1 study of TAVO412, an anti-EGFR, cMET, and VEGF-A multi-specific antibody. PATIENTS AND METHODS Patients of age ≥18 years with advanced solid tumors refractory to standard therapies were enrolled (TAVO412-CN001, NCT06761651). The study used a standard 3 + 3 design for dose-es...

Chao Han, Hong Xie, Yan Yu et al. · 0 citations
Review Open access Oct 2026

Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial.

PURPOSE MET amplification accounts for up to 30% of acquired resistance to EGFR-TKI, especially following third-generation EGFR-TKI treatment, yet precision-targeted therapeutic options remain limited. Early-phase studies demonstrated promising antitumor activity with the MET-TKI dalmelitinib combined with the third-ge...

Zi-Ming Li, Xiao-Rong Dong, Yan Yu et al. · 0 citations
Review Oct 2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

BACKGROUND Ruzaltatug rezetecan is a novel HER3-directed antibody-drug conjugate that has shown promising antitumour activity and manageable safety in pretreated EGFR-.mutated non-small-cell lung cancer (NSCLC) in a phase 1 trial. We aimed to compare the efficacy and safety of ruzaltatug rezetecan with chemotherapy in...

Chong-Rui Xu, Yan Zhang, G. Lin et al. · 1 citation
Review Aug 2026

Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial.

Findings support sutetinib as a potential treatment option for this molecularly heterogeneous population of adults with locally advanced or metastatic NSCLC harboring uncommon EGFR mutations and demonstrate clinically meaningful antitumor activity with a manageable safety profile.

Feng-Ying Wu, Wei Zhang, Yan-Qiu Zhao et al. · 0 citations
Review Open access Aug 2026

The neuro–immune–vascular landscape of lung cancer brain metastasis: insights from organoid models

Lung cancer brain metastasis (LCBM) is a major cause of cancer-related mortality, driven by the restrictive blood–brain barrier (BBB), an immunosuppressive microenvironment, and dynamic metabolic reprogramming. Increasing evidence suggests that LCBM is governed by coordinated interactions among neural, immune, and vasc...

Jiaojiao Li, Mingjun Xu, Lei Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.